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Abstract
Background: Structural variation in the neurexin-1 (NRXN1) gene increases risk for both autism spectrum disorders (ASD)
and schizophrenia. However, the manner in which NRXN1 gene variation may be related to brain morphology to confer risk
for ASD or schizophrenia is unknown.
Method/Principal Findings: 53 healthy individuals between 18–59 years of age were genotyped at 11 single nucleotide
polymorphisms of the NRXN1 gene. All subjects received structural MRI scans, which were processed to determine cortical
gray and white matter lobar volumes, and volumes of striatal and thalamic structures. Each subject’s sensorimotor function
was also assessed. The general linear model was used to calculate the influence of genetic variation on neural and cognitive
phenotypes. Finally, in silico analysis was conducted to assess potential functional relevance of any polymorphisms
associated with brain measures. A polymorphism located in the 39 untranslated region of NRXN1 significantly influenced
white matter volumes in whole brain and frontal lobes after correcting for total brain volume, age and multiple
comparisons. Follow-up in silico analysis revealed that this SNP is a putative microRNA binding site that may be of functional
significance in regulating NRXN1 expression. This variant also influenced sensorimotor performance, a neurocognitive
function impaired in both ASD and schizophrenia.
Conclusions: Our findings demonstrate that the NRXN1 gene, a vulnerability gene for SCZ and ASD, influences brain
structure and cognitive function susceptible in both disorders. In conjunction with our in silico results, our findings provide
evidence for a neural and cognitive susceptibility mechanism by which the NRXN1 gene confers risk for both schizophrenia
and ASD.
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Introduction
Autism Spectrum Disorders (ASDs) and schizophrenia are
highly heritable disorders with genetic factors comprising the
majority of the known risk [1]. Currently, the gene with the best
evidence for shared susceptibility for schizophrenia and ASD is the
Neurexin-1 (NRXN1) gene, one of the largest known human genes
(1.1 Mb) with 24 exons, located on chromosome 2p16.3 [2]. The
NRXN1 gene encodes the neurexin-1a and neurexin-1b proteins
that function as pre-synaptic neural adhesion molecules. Neurexin-
1a is reported to interact with postsynaptic neuroligins (NLGNs)
mediating GABAergic and glutamatergic synapse function [2]. It
also has been reported to bind to leucine-rich repeat trans-
membrane protein (LRRTM2) [3], instructing presynaptic and
mediating postsynaptic differentiation of glutamatergic synapses.
Substantial evidence implicates deletions in the NRXN1 gene in
ASD [4–10] and schizophrenia [11–17]. NRXN1 has also been
associated with mental retardation [18,19], nicotine dependence
[20–22], alcoholism [23] and vertebral anomalies [24]. Therefore,
it is apparent that disruptions of the NRXN1 gene, especially
deletions, confer risk to a range of neurodevelopmental pheno-
types, including ASDs, schizophrenia, and mental retardation.
The results of neuroimaging studies suggest that schizophrenia
and ASD patients also share neural vulnerability, most notably in
the frontal lobe and in frontal lobe circuitry [25,26]. Therefore,
genes that confer susceptibility to both schizophrenia and ASD
might contribute to altered brain structure and/or function
common to both disorders. Although few studies have included
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20982both ASD and schizophrenia patients, overlapping findings
between these illnesses occur most prominently in the frontal lobe
and in fronto-striatal circuitry [25,26]. Grey and white matter in
ASD has been associated with increased cortical grey to white
matter ratio and decreased volumes beyond childhood [27,28].
Although both increases and decreases in grey and white matter
volumes in ASD have been reported, white matter abnormalities
in the frontal lobe remain some of the most consistent
neuroimaging findings in ASD [29–36]. Thus, developmental
abnormalities in white matter growth seems important in the
etioneuropathology of ASD [37]. Structural MRI findings in
schizophrenia populations are typically characterized by decreases
in temporal and frontal lobe volumes, and some reductions in total
brain volume and parietal volumes [38,39]. Although findings
have not always been consistent, a recent meta-analysis of 17
studies confirmed a frontal lobe white matter deficit in patients
with schizophrenia [40]. Furthermore, cytoarchitectural altera-
tions of the prefrontal cortex have been found in schizophrenia,
and decreased thalamic volume and altered prefrontal-thalamic
circuitry are common findings in this disorder [41–47]. Altogether,
these findings suggest abnormalities of frontal, thalamic, and
striatal structure that may be shared in the neuropathology of
schizophrenia and ASD. Neurocognitively, sensorimotor deficits
are shared by both disorders. Such deficits are typically apparent
in ASD patients [48]. Cognitive assessment [49] and birth cohort
studies [50] also identify impaired sensorimotor function in
schizophrenia.
The intermediate phenotype approach permits us to examine
how shared genetic underpinnings of these two disorders may
confer risk in the brain [51–53]. Therefore, we used this approach
to investigate 11 single nucleotide polymorphisms (SNPs) of the
NRXN1 gene lying within regions overlapped by numerous
deletions implicated in ASD and schizophrenia, and their effects
on brain morphometry in healthy individuals. Given that such
deletions confer susceptibility to both schizophrenia and ASD, we
hypothesized that NRXN1 polymorphisms would confer an
intermediate phenotype related to schizophrenia and ASD, via
effects on neural structures and cognitive function altered in both
disorders.
Results
Genotypes
Concordance for the 10% of re-genotyping of all 11 SNPs
(Figure 1) was 100%. No SNP deviated significantly from Hardy-
Weinberg equilibrium. Four SNPs (rs10208208, rs12623467,
rs10490162, 10490227) were not included in further analysis
since their minor allele frequency (MAF) was below 15% (Table
S1). Furthermore, none of the SNPs was in linkage disequilibrium
(LD) (not shown), and their MAF was similar to the Hapmap CEU
population [54]. For rs1045881 since only one TT homozygote
was in the sample, we combined T-allele carriers (T/T and T/C)
and collectively analyzed in one cell. Post hoc independent t-tests
of rs1045881 genotype (T-Carriers vs. C/C) revealed no
significant differences in any demographics measured (Table S2).
For lobar gray matter volumes, no genotype by brain region
interactions or main effects of genotype were found following
repeated measure ANCOVAs conducted for each of the seven
SNPs with MAF.15%, with age and total brain volume as
covariates. Therefore, no follow-up analysis was performed. When
examining white matter volumes, we found that for each lobe,
a minimum of 85% of the variance in one hemisphere was
explained by the white matter volume of the other hemisphere
(P,0.001, R
2
(Pearson).0.85); therefore, we combined lobar white
matter volumes across hemispheres. For lobar white matter
volumes, a genotype by white matter lobe volume interaction
was found following repeated measures ANCOVA, at the
rs1045881 (F2.25=5.498, p=0.004) and rs858932 (F4.56=3.802,
p=0.004) polymorphisms (Bonferroni corrected alpha of 0.0071).
We did not observe significant white matter region volume by
genotype interactions in any other NRXN1 variants examined. The
results for the rs1045881 and rs858932 SNPs were followed up
using separate ANCOVAs for white matter volume at each lobe.
The rs1045881 variant was significantly associated with frontal
lobe white matter volume (Bonferroni corrected alpha=0.0125 for
four brain regions): F1,49=8.231, p=0.006; (Figure 2), where ‘CC’
homozygotes demonstrated reduced frontal white matter volumes
compared to ‘T’ allele carriers. Consistent with the direction of
effect in frontal lobe, the rs1045881 was nominally associated (as it
did not survive Bonferroni correction) with change in parietal lobe
white matter volume (F1,49=4.089, p=0.049). No association of
this SNP with temporal or occipital lobe white matter volume was
observed.
The follow-up ANCOVA examining rs858932 genotype also
predicted frontal lobe white matter volume (F2,51=5.472,
p=0.007), where ‘GG’ individuals had lower frontal lobe white
matter volume and nominal association in the parietal lobe also
occurred in the same direction, but did not survive Bonferroni
correction (F48,2=3.719, p=0.032; Figure S1). Frontal lobe white
matter volumes were also associated at the allelic level: both the
‘C’ allele of rs1045881 (x
2=7.184, p=0.0074) and the ‘G’ allele of
rs858932 (x
2=4.121, p=0.0432) predicted lower frontal white
matter volume (Table S3). Similar results were shown in the
haplotype analysis (p(Global),0.001; Table S4).
Repeated measures analysis for striatal and thalamic structures
revealed a significant volume by region interaction for the
rs858932 SNP only (F14,336=3.4, p,0.001; Greenhouse-Geiser
correction: F4,99=3.4, p=0.01). Follow-up ANCOVAs at left and
right caudate, putamen, globus pallidus, and thalamus revealed
that this interaction was driven by the influence of the rs858932
SNP on thalamic volumes only: for left thalamus (F2,48=8.9,
p=0.001), and for right thalamus (F2,48=7.3, p=0.002),
significant at the Bonferroni corrected alpha for eight comparisons
(alpha=0.0063, Figure 3). Here, ‘GG’ individuals had significantly
lower thalamic volumes compared to ‘T’ allele carriers. No
significant effects were observed at caudate, putamen, or globus
pallidus.
Cognitive
Repeated measures ANCOVA showed a main effect of the
rs1045881 SNP on sensorimotor function (F1,49=4.8, p=0.03).
The ‘C/C’ homozygotes had reduced finger tapping scores
compared to ‘T’ allele carriers, consistent with the directional
effect on white matter volumes. No association was observed for
the rs858932 SNP (F1,48=0.4, p=0.67). No task by genotype
interaction was observed for either polymorphism.
Frontal lobe white matter volume was highly correlated with
finger tapping (FT) score even after accounting for age effects
(Dominant Hand: R
2=0.404, p=0.003; Non-Dominant Hand:
R
2=0.469, p=0.001).
In silico analysis
The rs1045881 SNP is located in the 39UTR of Neurexin-1. In
silico prediction by miRBase analysis revealed the presence of the
C-allele creates a binding site for the microRNA hsa-miR-1274a
and hsa-miR-339-5p. Furthermore, alteration in exon splicing
enhancer and other motifs were observed. The rs858932 SNP was
Neurexin-1: Neural Risk for Schizophrenia and ASD
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silico prediction.
Discussion
We found that genetic variation in the 39untranslated region of
the NRXN1 gene predicted an intermediate risk phenotype in
healthy individuals relevant to schizophrenia and ASD. Our
primary finding at the rs1045881 SNP in the 39UTR of Neurexin1
demonstrated that the ‘C’ allele predicts reduced frontal white
matter volume and sensorimotor function. Furthermore, our in
silico analysis suggested presence of the same ‘C’ allele predicted
microRNA binding, thus providing a potential mechanism for this
allele’s effects on brain structure and cognitive function. The gene
variants that influenced brain morphology in our study are located
in the regions of NRXN1 susceptible to deletion in schizophrenia
and ASD. The effects of these genetic variants localized to brain
structure and cognitive function that demonstrate overlapping
susceptibility in both schizophrenia and ASD, namely frontal lobe
white matter abnormalities, as shown in recent meta-analyses
[40,55] and sensorimotor function [56–59]. To our knowledge,
this work provides the first evidence in vivo of how variation in the
NRXN1 gene may confer a potential neural risk mechanism for
schizophrenia and ASD.
Schizophrenia and ASD patients share sensorimotor deficits
and soft neurological signs [60]. Such shared deficits are almost
certainly neurodevelopmental in nature, as in ASD they present at
a very early age, and when present in schizophrenia, they are often
present before illness onset. White matter, likely through
myelination, plays a key role in ensuring appropriate sensorimotor
development, and motor tasks and motor speed are tightly
correlated with white matter indices on MRI [61,62]. Our finding
correlating white matter volumes with sensorimotor performance
is consistent with previous investigations [33,63,64]. Moreover, the
Figure 1. Reported Deletions in the Neurexin-1a gene. Figure contains the location of gene, markers, and reported deletion in: developmental
disorders (green; Ching et al. [18]), schizophrenia (red; Rujescu et al. [13], Vrijenhoek et al. [14], Magri et al. [96], Ikeda et al. [15], Need et al. [12]), and
autism spectrum disorders (blue; Pinto et al. [97], Glessner et al. [17]. The Autism Chromosome Rearrangement Database [6]). Figure adapted from the
UCSC genome browser (GRCh37/hg19 assembly) [98].
doi:10.1371/journal.pone.0020982.g001
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presumably increased enzymatic breakdown of NRXN1 mRNA
and reduced NRXN1 translation) also correlates with reduced
white matter volumes and altered sensorimotor function.
Our second finding was that the intronic rs858932 SNP, also
located in a deletion site [13,14,18], similarly influenced frontal
lobe white matter volume, but also prominently influenced left and
right thalamic volumes. We consider this finding more preliminary
Figure 2. The effect of rs1045881 on combined hemispheric volume of brain regions with total brain volume (TBV) and age as
covariates. Brain regions: (A) Frontal Lobe, (B) Temporal Lobe, (C) Occipital Lobe, and (D) Parietal Lobe. Frontal lobe white matter volume was
significantly greater in T allele carriers (T/T +T/C) (ANCOVA F1,52=8.197, p=0.006), while other regions are non-significant after correcting for multiple
comparisons. Covariates appearing in the model are evaluated at the following values: TBV=1364768.17, Age=39.04, (*) denotes significance of
P,0.0125. Error bars represent +/2 standard error of the marginal means and percentages reflect the percent change in each brain region.
doi:10.1371/journal.pone.0020982.g002
Figure 3. The effect of rs858932 on right and left thalamic volume with TBV and age as covariates. There are approximately 10% and 9%
percent differences between the G/G to G/C and G/G and C/C genotypes for both thalamic hemispheres, respectively. Covariates appearing in the
model are evaluated at the following values: TBV=1364768.17, Age=39.04, (*) denotes significance of P,0.0063. Error bars represent +/2 standard
error of the marginal means.
doi:10.1371/journal.pone.0020982.g003
Neurexin-1: Neural Risk for Schizophrenia and ASD
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20982due to the lower minor allele frequency at this variant in our
sample. Nevertheless, association of this variant with thalamic
volumes is consistent with overlapping neural vulnerability for
ASD and schizophrenia as well [39,65], and suggests that the
NRXN1 gene may influence thalamocortical circuitry that is
vulnerable in both disorders.
Little is known about how specific types of deletions within the
NRXN1 gene may relate to a given neuropsychiatric phenotype.
Our in silico analysis demonstrated the 39UTR SNP as a putative
microRNA binding site for hsa-miR-339 and hsa-miR-1274, thus
suggesting a functional role for this region of the gene that may
relate to mRNA expression of NRXN1. This is interesting since
expression of miR-339 microRNA has been reported to be
dysregulated in the cortex of psychotic patients [66]. Reduced
NRXN1 mRNA may influence white matter alterations by
concomitant reductions in binding to the NRXN1 binding partner,
LRRTM2, which mediates postsynaptic differentiation of gluta-
matergic synapses [3,67,68]. Glutamatergic dysfunction is well
established in schizophrenia [69]; further, NXRN1 expression is
induced by AMPA receptors, and mediates recruitment of NMDA
receptors, a hallmark of synapse maturation [70]. Glutamatergic
dysfunction can also lead to white matter abnormalities.
Oligodendrocytes possess glutamatergic receptors (both AMPA
and NMDA), and are highly sensitive to any form of stress or
toxicity [71]. Therefore, NRXN1 may influence frontal white
matter in schizophrenia and ASD through disrupted interaction
with its glutamatergically-related binding partners, or possibly via
direct glutamatergic involvement as the NRXN1 knock out mouse
demonstrates decreased excitatory synaptic strength and decreased
prepulse inhibition [72].
Recent imaging-genetics studies [73,74] have implicated
a neurexin superfamily member, the contactin-associated protein-like
2 (CNTNAP2) gene in brain structure and function providing
evidence for neural susceptibility patterns relevant to ASD. These
studies demonstrated volumetric reductions for CNTNAP2 risk
allele carriers particularly in frontal lobe [73,74] and also showed
altered frontal connectivity. One of these two studies [74]
demonstrated strong effects with sample sizes smaller than ours.
Our findings, in conjunction with the recent imaging-genetics
findings of CNTNAP2 demonstrate the value of examining
common variants within known ASD risk genes to understand
neural susceptibility mechanisms conferred by these risk genes.
The ‘added-value’ of this approach lies in the neural localization of
gene effects, providing information regarding how the genes may
confer brain risk patterns for these disorders.
There are several limitations in our study that should be
considered. First, we imposed a dominant model by combining
genotypic groups C/T and T/T at rs1045881; however concern
regarding this model can be mitigated by our findings that allelic
association analysis supported such a model. Second, one could
argue that our finding may constitute a ‘winner’s curse’, and
therefore we would encourage replication efforts. A third limitation
of our study is that while there was a clear effect of this putative risk
variant onfrontal lobe whitemattervolume, ina directionconsistent
with cognitive function findings and in silico prediction, various MRI
studies have reported either reductions or increases in frontal lobe
white matter for both populations. Finally, given that we measured
gray and white matter volumes for cortical lobar structures, we were
somewhat limited in obtaining more localized regional specificity for
effects of NRXN1 variation. More detailed parcellation, white matter
voxel-based morphometry, or other white matter imaging tech-
niques such as diffusion tensor imaging, magnetization transfer
imaging, or T2 techniques should help clarify further the manner in
which NRXN1 influences frontal white matter.
In summary, we found that variants within the NRXN1 gene
influence brain morphometry with a susceptibility pattern relevant
to both schizophrenia and ASD. This finding is consistent with the
fact that NRXN1 is a vulnerability gene for both disorders. In
addition to reporting that the rs1045881 gene variant is associated
withfrontalwhite mattervolumeand sensorimotor performance, we
provideaputativemechanisticexplanationforitseffectsinthebrain.
Taken together, our findings provide evidence that genetic variation
in NRXN1, a risk gene for schizophrenia and ASD, may confer
neural and cognitive susceptibility common to both disorders.
Materials and Methods
Participants
Fifty-three healthy volunteers (15 women, 38 men) (Table 1)
met the following eligibility criteria: age between 18 and 59; right
handedness; absence of any history of a mental disorder, current
substance abuse or a history of substance dependence, positive
urine toxicology, history of head trauma with loss of consciousness,
seizure, or another neurological disorder; no first degree relative
with a history of psychotic mental disorder. All participants were
assessed with the Edinburgh handedness inventory [75] for
handedness, Wechsler Test for Adult Reading (WTAR) for IQ,
and Hollingshead index for socio-economic status [76]. They were
interviewed by a psychiatrist, and completed the Structured
Clinical Interview for DSM-IV Disorders [77]. They also
completed a urine toxicology screen. The study was approved
by the Research Ethics Board of the Centre for Addiction and
Mental Health (Toronto, Canada) and all participants provided
informed, written consent.
Neuroimaging
High resolution magnetic resonance images were acquired as
part of a multi-modal imaging protocol using an eight-channel
head coil on a 1.5 Tesla GE Echospeed system (General Electric
Medical Systems, Milwaukee, WI), which permits maximum
gradient amplitudes of 40 mT/m. Axial inversion recovery
prepared spoiled gradient recall images were acquired: echo time
(TE)=5.3, repetition time (TR)=12.3, time to inversion
(TI)=300, flip angle=20, number of excitations (NEX)=1 (124
contiguous images, 1.5 mm thickness).
Image Processing
Each subject’s T1 image was submitted to the CIVET pipeline
(version 1.  1.  7)   developed    at    the  Montreal    Neurological
Institute [78].  The  processing  steps  included  registration 
to   the symmetric ICBM  152    template  [79]  with  a  12-
parameter linear transformation [80],    correction      for   inhomo-
geneity artifact [81], skull stripping [82],  tissue  classification
into white and grey matter, cerebrospinal fluid
Table 1. Demographic Characteristics.
Mean± St. Dev. Range
Age 39.0613.1 19–59
Education (years) 15.662.0 12–20
IQ (WTAR) 118.267.7 92–127
Socioeconomic Status
a 50.069.8 27–66
WTAR, Wechsler Test of Adult Reading.
aComposed of four factors are education, occupation, sex, and marital status.
doi:10.1371/journal.pone.0020982.t001
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 and background [83,84] and neuroanatomical segmentation using
ANIMAL [85]. Total volumes for each cortical lobe and
subcortical structures were estimated for each individuals by
non-linearly warping each T1 image towards a segmented atlas
[86]. Volume (mL) was extracted from each of these regions using
the RMINC package (version 0.4) for reading and analyzing
MINC2 output files. Total gray matter, white matter, and CSF
volumes were calculated, along with lobar cortical gray and white
matter volumes (i.e., left and right frontal, temporal, parietal,
occipital), along with volumes of subcortical structures related to
the fronto-striato-thalamic loop implicated in both schizophrenia
and ASD including left and right caudate, putamen, globus
pallidus, and thalamus.
Genetics
Genomic data was extracted from ethylenediametetraaecidic
acid (EDTA) anticoagulated venous blood according to standard
procedures. Eleven SNPs were genotyped on an Applied
Biosystems ABI 7500 Real-Time PCR system, using Taqman 59
nuclease assay. Genotyping accuracy was assessed by running 10%
of the sample in duplicate. Eleven SNPs were selected across the
NRXN1 gene (NC_000002.11). Each marker is located in reported
regions within which multiple rare deletions associated with ASD
and schizophrenia (Figure 1, Table S5).
The program Haploview 4.2 [87] was used to determine pair-
wise LD between all SNPs with blocks determined by the Gabriel
et al. method [88]. Haploview 4.2 was also used to determine
whether SNPs were in Hardy Weinberg equilibrium.
Cognitive assessment
Fifty-two of the study participants completed cognitive testing
that included the finger-tapping test [89–91]. Although cognitive
deficits in ASD are not as well-characterized as those in
schizophrenia, sensorimotor function is disrupted in both disorders
[92–95]. Therefore, we used the finger-tapping test to assess
sensorimotor function.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows
15.0. To test for effects of NRXN1 genotype on brain morphom-
etry, three separate repeated measures ANCOVA (for cortical
lobar gray matter, cortical lobar white matter, and subcortical
structures) were performed with genotype as the between group
factor, brain region volume as the within group factor, and age
and total brain volume (TBV) as covariates. To ensure adequate
power, only markers with a minor allele frequency (MAF) greater
than 15% were tested. We used a Bonferroni correction based on
multiple comparisons of 7 SNPs to determine significance
(alpha=0.0071). Where the repeated measures ANCOVA
revealed a significant volume by genotype interaction, follow-up
ANCOVAs were performed and Bonferroni correction applied.
When significant effect of a genotype on brain volume was found,
UNPHASED 3.1 was then used to examine allelic association with
brain phenotypes. Haplotype quantitative analysis of frontal lobe
white matter volume and the rs1045881 and rs858932 NRXN1
variants were calculated using haplotype score (Methods S1).
Finally, for those genotypes that significantly predicted brain
measures, repeated measures ANCOVA for sensorimotor function
was performed (dominant and nondominant finger-tapping scores
as within group measures) with age as covariate. For any gene
variant that predicted both brain measures and cognitive
performance, the relationship between that brain measure and
cognitive performance was examined using a linear regression
model, accounting for age effects.
In Silico Analysis
In order to enhance the understanding of the biological
meaningfulness of the genetic associations, we used in silico
methods to predict potential function of the SNPs investigated in
this study. Depending on their location, SNPs were assessed for
alteration in transcription factor binding using MatInspector
(Genomatix; promoter and intron 1). Presence of splicing
enhancers, repressors or intronic regulatory elements (intronic
and exonic, synonymous and nonsynonymous SNPs) were
determined using F-SNP (http://compbio.cs.queensu.ca/F-SNP)
and Human Splicing Finder (http://www.umd.be/HSF ). 39UTR
SNPs were also assessed for alteration in microRNA binding sites
(http://www.targetscan.org/).
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spheric volume of brain regions with TBV and age as
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Age=39.04, (*) denotes significance of P,0.0125. Error bars
represent +/2 standard error of the marginal means and
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